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Abstract: Crown ethers are cyclic molecules consisting of a ring containing several ether groups. 
The most common and important members of this series are 12-crown-4 (12C4), 15-crown-5 
(15C5), and 18-crown-6 (18C6). These container molecules have the ability to sequester metal 
ions and their complexes with drugs are able to traverse cell membranes. This study investigated 
12C4, 15C5 and 18C6 for their ability to increase solubility of ocular drugs and enhance their 
penetration into the cornea. Phase solubility analysis determined crown ethers’ ability to enhance 
the solubility of riboflavin, a drug used for the therapy of keratoconus, and these solutions were 
investigated for ocular drug permeation enhancing properties. Atomic absorption spectroscopy 
demonstrated crown ether solutions ability to sequester Ca2+ from corneal epithelia and crown 
ether mediated adsorption of riboflavin into the stroma was investigated. Induced corneal opacity 
studies assessed potential toxicity of crown ethers. Crown ethers enhanced riboflavin’s aqueous 
solubility and its penetration into in vitro bovine corneas; the smaller sized crown ethers gave 
greatest enhancement. They were shown to sequester Ca2+ ions from corneal epithelia, doing so 
loosens cellular membrane tight junctions thus enhancing riboflavin penetration. Induced corneal 
opacity was similar to that afforded by benzalkonium chloride and less than is produced using 
polyaminocarboxylic acids. However, in vivo experiments performed in rats with 12C4 did not 
show any statistically significant permeability enhancement compared to enhancer-free 
formulation.  
 
Keywords: Crown ethers, corneal epithelium, ocular drug delivery, riboflavin, permeability 
enhancement, toxicity, in vitro-in vivo correlation. 
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Introduction 
Eye drops are generally the preferred means to apply medication when treating ocular disorders; 
they are convenient and easy to use for most patients. However, this has difficulties despite the 
fact that the eye is easily accessible since effective drug delivery requires several barriers to be 
overcome.  With aqueous formulations, delivering lipophilic or poorly water soluble drugs at an 
effective concentration is problematic as is blinking, tear washout and nasolacrimal drainage 
mechanisms.  Up to 90% of the instilled dose is lost almost immediately; more is absorbed 
systemically to be eliminated by metabolic processes.  It is estimated that <1% of the instilled dose 
penetrates into the eye.1,2 When medication is introduced onto the eye there remains only a short 
time during which the drug can penetrate the cornea.3 
Corneal epithelium is a lipophilic structure with tight junctions at the superficial cell layers. This 
layer offers a resistant barrier which impedes penetration of drug molecules in aqueous solution. 
However, the underlying stroma, which comprises ~90% of the cornea thickness has a hydrophilic 
gel-like structure and drugs in aqueous solution easily diffuse throughout this layer.3,4 
Keratoconus is a debilitating condition of the cornea which can be treated using riboflavin to 
initiate ultraviolet ‘A’ induced collagen cross-linking.5 This treatment has become routine practice 
for the treatment of keratoconus and other corneal disorders.6-9 However, the procedure relies on 
the physical removal of the epithelium under local anaesthesia to allow stromal penetration of 
riboflavin.5 Developing a means to deliver riboflavin into the cornea without removal of the 
epithelium would be a significant improvement over the current procedure. 
Compounds that are effective at extracting Ca2+ ions have been reported to enhance ocular drug 
permeability.10 Polyaminocarboxylic acids are a class of compound well known for Ca2+ 
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sequestration11-14 and we have demonstrated this in a recent study using calcium chelators for 
improved ocular drug delivery.15 
Crown ethers are a class of synthetic macrocyclic polyether molecules first synthesized in the 
1960’s.16 With their electron rich hydrophilic cavity due to the lone pairs associated with their 
oxygen atoms (where cation binding occurs), these molecules have a hydrophobic molecular ring 
structure, and are able to form guest-host complexes with metal ions and neutral organic 
molecules. It is thought that these ligands have better affinity to the metal cation on the basis of 
what fits in the inner cavity. The ‘cavity-size’ relationship was initially used as the underlying 
concept to explain binding strength and selectivity and suggested that the binding strength will be 
highest when the ionic diameter of a cation and the cavity of the crown ether are equal.17 However, 
this principle has been revised with the most significant factors now considered to be pre-
organisation and complementarity, solvation and chelate ring size.18 The inherent flexibility of 
crown ethers allows them to adapt to a range of environments, displaying solubility in aqueous 
and lipophilic solvents and ‘rapid, reversible ion binding characteristics’.18 According to the 
Hansch lipophilicity scale, 18C6 has a value of zero, indicating a perfect hydrophilic / lipophilic 
balance. This is due to the ligand’s ability to flex according to the medium it encounters, exposing 
either hydrophilic oxygen atoms or lipophilic ethylenic groups.18 This is desirable for ocular drug 
delivery since the physiology of the eye means that a formulation has to traverse lipid and aqueous 
phases, and the relatively short residence time means enhancing permeation will allow for greater 
drug absorption.  
Crown ethers have uses in many fields; chemistry, biology, industrial and pharmacological 
research. Their complexes are able to cross cellular membranes.19-21 Crown ethers are used in other 
therapeutic areas, such as tumour treatment,22 and they have been investigated for enhancement of 
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drug delivery via vesicular formulations,23,24 but as far as we know they have not  been investigated 
for ocular drug delivery.  We hypothesized that if these compounds can form complexes with 
calcium ions they should be able to make the cornea more permeable to drugs by extracting Ca2+, 
thereby loosening epithelial tight junctions, and their ionophoric properties could assist transit of 
polyether/drug complexes across corneal epithelium. 
In this study we investigated the effects of 3 cyclic polyethers of increasing ethylene oxide units, 
12C4, 15C5 and 18C6 for their ability to bind and extract Ca2+ and whether they afford any 
enhancement to the solubility of riboflavin and its corneal penetration. Isothermal titration 
calorimetry (ITC) was used to analyse their Ca2+ binding properties and atomic absorption 
spectrometry (AAS) employed to determine their ability to extract Ca2+ from corneal epithelium. 
High performance liquid chromatography (HPLC) was employed to determine riboflavin 
solubility enhancement and in vitro experiments using Franz diffusion cells (FDC) to determine 
drug permeation through whole corneas. Bovine corneal opacity and permeability (BCOP) was 
used to determine toxicological implications from the use of crown ethers. In vivo experiments 
were performed in rats, but did not establish any statistically significant ocular permeability 
enhancement in live animals.  
 
Materials and Methods 
Materials.  Crown ethers (12C4, 15C5 and 18C6), 2-(N-morpholino)ethanesulfonic acid (MES), 
riboflavin, glacial acetic acid, sodium hexane-1-sulfonate monohydrate, benzalkonium chloride 
(BAC), ethylenediaminetetraacetic acid (EDTA) and fluorescein sodium salt were supplied by 
Sigma-Aldrich (Gillingham, UK). Calcium calibration standard (1000 ppm), 10% w/v lanthanum 
chloride, calcium chloride, potassium chloride, sodium chloride, sodium phosphate, potassium 
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dihydrogen phosphate, sodium hydroxide (NaOH), hydrochloric acid, optimal cutting temperature 
compound (OCT), and HPLC grade ethanol were obtained from Fischer Scientific (Hemel 
Hempstead, UK). Vectashield mounting medium with 4’,6-diamidino-2-phenylindole (DAPI) was 
obtained from Vector Laboratories Ltd (Peterborough, UK). Ultrapure water (18 mΩ cm-1) was 
used for all aqueous solutions and all materials were used as supplied without modification.   
Preparation of buffer solutions    
Isotonic phosphate buffered saline (PBS) pH 7.4 ± 0.2, 10 mM 2-(N-morpholino)ethanesulfonic 
acid buffer (MES) pH 7.4 ± 0.2 and 0.005 M sodium hexane-1-sulfonate, pH 3.0 ± 0.2 (ion-pair 
buffer) was prepared in-house using established protocol. 0.005 M ion-pair buffer for HPLC 
analysis was prepared by dissolving 1.8822g sodium hexane-1-sulfonate monohydrate to 1800 mL 
ultrapure water adjusted to pH 3.0 ± 0.2  using glacial acetic acid then made up to 2000 mL with 
ultrapure water and filtered to 0.2 µm. For isothermal titration calorimetry, 10 mM MES buffer 
was prepared by dissolving 390.48 mg 2-(N-morpholino)ethanesulfonic acid in 180 mL ultrapure 
water adjusted to pH 7.4 ± 0.2  using 1 M NaOH solution then made up to 200 mL with ultrapure 
water and filtered to 0.2 µm.25,26   
HPLC analysis for in vitro experiments 
HPLC analysis was conducted using a Perkin Elmer series 200 system including UV-Vis detector, 
quaternary pump and autosampler (Perkin Elmer Inc, UK), a 150 mm × 4.1 mm, 10 μm, reversed 
phase column, part number: 79425 (Hamilton Company, USA) and PeakSimple data acquisition 
software version 4.09 (SRI Inc, USA).  Riboflavin analysis was achieved using the method 
previously developed by us. Briefly, isocratic analysis over 5 minutes at 25°C, 0.8 mL per minute 
pre-mixed mobile phase consisting of 20% ethanol and 80% ion-pair buffer, 267 nm wavelength, 
10 μL injection volume and riboflavin retention time of 3.05 minutes. Analysis was quantified 
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against a calibration curve produced from riboflavin standards in PBS, pH 7.4 ± 0.2 with a range 
of concentrations between 0.01 to 25 µg mL-1 (r2 = 0.9996).15 
 
Atomic absorption spectroscopy 
Calcium analysis was achieved using a novAA 350 system with WinAAS software, version 4.5.0 
(Analytik JENA, Germany). The analytical method as published by Whiteside and Milner was 
followed; 50 mm stoichiometric air/acetylene flame, 422.7 nm wavelength, ultrapure water (18 
mΩ cm-1) as the carrier.27 Analysis was quantified against a calibration curve produced from 
aqueous Ca2+ standards with 5% lanthanum chloride as a releasing agent. Standards were prepared 
at concentrations between 0.1 to 10.0 ppm (r2 = 0.9921).  
Isothermal titration calorimetry   
Ca2+/crown ether binding properties were determined using isothermal titration calorimetry (ITC).  
A Microcal calorimeter, model ITC200 with software version 1.24.2 (MicroCal Inc. USA). 
Ultrapure water was put in the reference cell and a reference power of 10 μCal s-1 was selected.  5 
mM solutions of crown ethers (12C4, 15C5, and 18C6) in 10 mM MES buffer (pH 7.4 ± 0.2) were 
titrated by 100 mM CaCl2 in 10 mM MES buffer.  Following the first (redundant) injection at 0.4 
µL, 15 further 2 µL injections were made with a spacing of 2.5 minutes and temperature of 25°C. 
Graphical analysis performed using Origin 7 SR4, v7.0552 software (OriginLab Corporation, 
USA).   
Preparation of animal tissues 
Fresh bovine eyes were sourced from a local abattoir (P C Turners, Farnborough, UK) and used 
within 24 hours after slaughter.  Experiments to determine calcium extraction and corneal opacity 
experiments employed whole eyes and excised corneas were used for in vitro permeability studies 
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using Franz diffusion cells. All experiments were triplicated with a separate eye or cornea used for 
each repeat. 
Whole eye experiments   
We have previously reported an experimental technique that we developed to investigate corneal 
exposure to drug formulation ns,28 the same protocol was employed in this investigation to 
determine Ca2+ extraction from corneal epithelia. Briefly, individual eyes were placed in beakers, 
cornea uppermost and packed with loosely rolled up clingfilm to prevent movement, Franz 
diffusion cell donor compartments were placed over the cornea and held in place by wrapping the 
whole assembly with clingfilm ensuring a good seal on the eye, the beakers were placed in a water 
bath at 34 C. After 10 minutes equilibration the corneas were exposed to aqueous crown ether 
solutions at either 1 mg mL-1 or 30 mg mL-1 at pH 7.4 ± 0.2. After three hours exposure the 
solutions were recovered, centrifuged at 10000 rpm (10 g) for ten minutes.  Aliquots of each 
supernatant were diluted by a factor of 100 in 0.25% aqueous LaCl3 solution for analysis by AAS. 
Effect of crown ethers on riboflavin solubility  
A series of aqueous crown ether solutions were prepared at 1, 10, 20 and 30 mg mL-1 for each 
molecular variant, 12C4, 15C5 and 18C6. To each solution an excess riboflavin was added at 1 
mg mL-1, and an aqueous solution of saturated riboflavin was used as a control.  These solutions 
were kept in glass vials, wrapped in aluminium foil and stirred overnight at room temperature.  
Riboflavin saturated solutions were filtered using 0.2 µm Minisart® syringe filters, then diluted 
with ultrapure water by a factor of 10 for HPLC analysis. Our previous studies have shown 
riboflavin to be photodegradable,28 and this agrees with data reported by Terekhova et. al.29 
therefore all experiments and samples were shielded from light using aluminium foil prior to 
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analysis. The association constants of complexation for the crown ethers and riboflavin were 
calculated using Equation 1. 
                                              �௔:௕ =  ௦�௢௣�[ௌ0][ଵ−௦�௢௣�]                                                             (1) 
Where Ka:b is the association constant, S0  is the intrinsic aqueous solubility of riboflavin and slope 
is the gradient given by the equation of the graph for riboflavin solubility in crown ether 
solutions.30,31 
Riboflavin solubility enhancement using crown ethers was calculated using Equation 2. 
                                        ���௥௢�௡ ሺ%ሻ  =  ∆ோ�ோ������  × ͳͲͲ%                                  (2) 
Where RFCrown(%) is crown ether enhanced riboflavin concentration, ∆RF is the difference 
between enhanced riboflavin concentration and the intrinsic aqueous concentration of riboflavin 
and RFwater is the intrinsic aqueous concentration of riboflavin.  
Effect of crown ethers on riboflavin permeability   
Solutions of 12C4, 15C5 and 18C6 crown ethers at concentration of 1 and 30 mg mL-1 in PBS, pH 
7.4 ± 0.2 were prepared; riboflavin was added at 0.08 mg mL-1 to dissolve. A solution of riboflavin 
in PBS, pH 7.4 ± 0.2 was also prepared at the same concentration as a control. Riboflavin 
permeability was measured using fresh bovine corneas fitted epithelium uppermost in standard 
Franz diffusion cells (FDC), each cell having an exposed area of cornea of 1.54 cm2. 16.5 mL of 
PBS was placed in the receiving chamber. Prepared FDCs were placed in a water bath, stirred at 
34°C ± 1°C to mimic the physiological temperature at the corneal surface.32,33 1 mL of aqueous 
crown ether solutions, and control was added to the donor compartments which were then covered 
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to prevent evaporation. 0.4 mL aliquots were sampled every hour for 4 hours using sink conditions. 
Analysis by HPLC was carried out immediately after all samples had been collected to avoid drug 
degradation.  Apparent permeability and steady-state flux were calculated using Equation 3. 
 
                                           �௔௣௣ = ∆ொ∆௧ 6଴ � �0                                            (3)  
Where Papp is the apparent permeability of riboflavin through bovine cornea, Q is total drug 
permeated at time t,  ∆Q/∆t is the steady-state flux into the receiving solution (µmol min-1) which 
equates to the gradient of the linear portion of the graph, 60 is minutes to seconds conversion 
factor, A is the area of exposed cornea (1.54 cm2) and Co is the initial amount of drug added to the 
donor chamber.31 
Cornea extracts 
Crown ether exposed corneas from the riboflavin permeability experiments were trimmed of 
scleral tissue, blotted dry and placed in vials containing 5 mL absolute ethanol to extract riboflavin. 
They were wrapped in foil, placed in a box and stored at room temperature for 3 days. After 
extraction, 1 mL of the extraction solvent was centrifuged for 10 minutes at 10000 rpm (10 g) and 
the supernatant analysed by HPLC. After riboflavin extraction the corneas were placed in an oven 
at 40°C overnight to dry and their weight recorded to allow calculation of absorbed riboflavin per 
mg dry corneal tissue.  
 
Toxicological investigation 
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Normal cornea's are transparent and impermeable to fluorescein dye due to tight junctions in the 
corneal epithelium.34 Application of a substance which can denature proteins or cause corneal 
injury, leading to permeation of the fluorescein dye, reflects toxicological effects to the epithelium. 
Using a method established in the Bovine Cornea Opacity/Permeability Test 35 (BCOP) described 
in,34 a scale of epithelial damage and fluorescent intensity was compiled. Corneal opacity and 
permeability was evaluated using the BCOP test in order to explore toxicological characteristics 
of crown ethers in comparison to known penetration enhancers and irritants, i.e. benzalkonium 
chloride and sodium hydroxide.  Fresh whole bovine eyes were placed in cups which were 
subsequently placed in 150 mL beakers, with the corneas facing uppermost. A few drops of PBS 
were applied to the corneal surface, the beaker was placed in a closed water bath at 34ºC ± 1ºC 
and allowed to equilibrate for 10 minutes. A silicon ring was placed on top of the cornea and 0.1 
mL of various solutions was applied, including PBS, 18C6 1 and 30 mg mL-1, 15C5 1 and 30 mL-
1, 12C4  30 mL-1, EDTA 1 mg mL-1, BAC 0.02%, BAC 0.1%, BAC 0.5%, BAC 1%,  BAC 2% 
and NaOH 0.5M and 1M.  The test solution was left on for 30 seconds before being washed off 
with 10 mL PBS. The beaker was then incubated for a further 10 minutes 34ºC ± 1ºC.  The eye 
was then removed from the beaker and photographed with the silicon ring still in place using a 
Logitech webcam C920-C, images included in supporting information (Table S1). Then 0.1 mL 
of 2% w/v fluorescein dye solution was placed in the ring and left for 1 minute. The ring was 
removed and the dye was washed off with 10 mL PBS. The eye was observed under the 
fluorescence microscope and the fluorescence image was acquired with the exposure set to 130 
ms, images included in supporting information (Table S2).  Both sets of images were processed 
using ImageJ 1.50b software V 1.8.0_60.  Each photograph was converted to 8-bit images, then 
the mean grey area function was used to measure opacity for the images, data included in 
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supporting information, (Table S3). Fluorescence image data shown in supporting information 
(Table S4).  The aim of this experiment was to assess any toxicity of crown ethers in comparison 
to known irritants, e.g. NaOH, and BAC 0.02% which is often used as a preservative and also as a 
penetration enhancer in ocular formulations.  
 
In vivo experiments 
All in vivo experiments reported in this work were approved by the Ethical committee of Kazan 
State Medical University (approval no 5 from 28th May 2012). These experiments were conducted 
with 0.08 mg mL-1 riboflavin solutions with and without 30 mg mL-1 12C4. These experiments 
were performed in 3 months Wistar male rats weighting 200-250 g. Animals were housed in 
stainless steel cages and were fed with a standard multi-ration pellets for rodents (Effect Ltd, 
Chapaevsk, Russian Federation) and had unlimited access to water. Each formulation was tested 
in 3 animals.  Each animal received 2 mL of the drug solution into both eyes, gradually instilled 
within 40 minutes. Then animals were sacrificed with a guillotine; both eyes were enucleated using 
scissors, weighed, quickly washed with 1 mL of 0.9 % saline solution  and  placed into 1 mL  
methanol for the drug extraction. Extraction was continued in a refrigerator at 4ºC for 24 hours; 
0.2 mL of each extract was then mixed with 0.8 mL 0.1 % of aqueous orthophosphoric acid 
followed by HPLC analysis. Separate experiments were performed to evaluate the retention of 
sodium fluorescein solutions on corneal surface in rats (n=3). A single drop of 1 mg mL-1 sodium 
fluorescein solution (~0.05 mL) was administered on rat’s cornea; UV light at 254 nm (VL-6.LC, 
Vilber Lourmat) was briefly shone into their eye to ensure the dye detection, which under these 
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conditions showed green fluorescence, and digital images were taken immediately and 5 minutes 
after drop administration. 
 
Histological studies 
All histological experiments were conducted similarly to the experiments on in vivo administration 
of riboflavin described in the previous section. Following 40 minutes administration of 1 mL 0.08 
mg mL-1 riboflavin solution with and without 30 mg mL-1 12C4 (n=3), rats were sacrificed with a 
guillotine; their eyes were enucleated and mounted in OCT and kept on dry ice. Cross-sectioning 
of each corneal segment was performed on a cryostat (Thermo Scientific Microm HM 525) and 
fixed on glass slides followed by application of 50−75 ȝL of 1.5 µg mL-1 DAPI to stain the cell 
nuclei. Cross sections of rat’s cornea were examined using fluorescence microscopy (Olympus 
BX63); each image was taken using DAPI (blue, maximum Ȝemission = 461 nm).  
 
HPLC analysis for in vivo experiments 
In order to improve the sensitivity of riboflavin detection in the eye extracts from in vivo 
experiments, a novel HPLC method was developed. HPLC analysis was conducted using a manual 
injection LC-20 Prominence HPLC system (Shimadzu, Japan) including SPO-20AV UV−vis 
detector, CTO-20A column oven, LC-20 AD-U solvent manager and Ascentis C18 column, 25 cm 
× 4.6 mm, 10 ȝm (part number: 581351-U), and data acquisition software (LCsolution version 
1.25). Riboflavin analysis was achieved with a run time of 6 min at 40 ºC. The mobile phase 
consisted of a mixture of 84 vol % of 0.1 vol % aqueous orthophosphoric acid and 16 vol % 
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acetonitrile, with a flow rate of 1.0 mL min−1, 445 nm wavelength, 10 ȝL injection volume and 
riboflavin retention time of 4.9 min. Analysis was quantified against a calibration curve produced 
from 0.02, 0.03, 0.05, 0.1, 0.2, and 1.0 µg mL-1 riboflavin standards (r2 = 0.9994). The results of 
these experiments are calculated in g of riboflavin per 1 g of fresh eye (g g-1).    
 
Statistical analysis 
Minitab® statistical analysis software package, version 16.2.4 was used to analyse data acquired 
during these experiments using one-way analysis of variance (ANOVA) and paired t-tests. 
Probability of P < 0.05 was considered significant and a minimum of triplicate experiments were 
used to determine this. Results are reported as the mean ± standard deviation. 
 
Results and Discussion  
Crown ether enhanced aqueous solubility of riboflavin 
It was shown that 12C4 at 1 mg mL-1 offered a slight reduction in riboflavin solubility at 0.074 ± 
0.003 mg mL-1** compared to the intrinsic aqueous solubility of riboflavin of 0.081 ± 0.004 mg 
mL-1,28,36,37 whilst all other crown concentrations 10, 20 and 30 mg mL-1 enhanced the solubility 
of riboflavin at 0.088 ± 0.003, 0.099 ± 0.004 and 0.110 ± 0.004 mg mL-1, respectively.**  15C5 
crown ethers at 1, 10, 20 and 30 mg mL-1 all enhanced riboflavin solubility to 0.094 ± 0.002, 0.104 
± 0.002,** 0.109 ± 0.002** and 0.118 ± 0.003*** mg mL-1, respectively, and 18C6 crown ethers 
at 1, 10, 20 and 30 mg mL-1 all enhanced riboflavin solubility to 0.095 ± 0.003, 0.100  ± 0.003, 
0.113 ± 0.003 and 0.115 ± 0.003 mg mL-1, respectively.**   *P<0.05 **P<0.005,   ***P<0.001, 
one way ANOVA, n = 3. 
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From the HPLC results, phase solubility analysis was carried out using the methods developed by 
Higuchi and Conners (1965)38 and reported by Jarho et al. (1996).31 Phase solubility plots were 
produced for mmol L-1 concentrations of the crown ether standards and their corresponding mmol 
L-1 riboflavin concentration, Figure 1.   
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Figure 1      Phase solubility plots for riboflavin / crown ether. Inserts show the structures of 12C4, 
15C5 and 18C6. 
 
Crown ether / riboflavin association constants Ka:b were calculated using Equation 1, and 
riboflavin solubility enhancement relative to its intrinsic aqueous solubility calculated using 
Equation 2.  It should be noted that the phase solubility plots for riboflavin with 15C5 and 18C6 
are not linear, which introduces some inaccuracy in determination of Ka:b compared to 12C4. At 1 
mg mL-1 crown ether reduced riboflavin solubility by -9% using 12C4** and enhanced riboflavin 
solubility by 16% for 15C5** and 17% for 18C6** and at 30 mg mL-1 they enhanced riboflavin 
solubility by 36% for 12C4,** 46% for 15C5*** and 42% for 18C6.***  Table 1 lists the 
concentrations of riboflavin in the various crown ether solutions together with the corresponding 
association constants and riboflavin solubility enhancement as a percentage relative to riboflavin 
in deionised water. 
 
Table 1   Crown ether / riboflavin association constant and enhanced solubility compared to 
riboflavin in de-ionized water. 
Crown ether /  Riboflavin  Association constant Riboflavin solubility  
riboflavin solution mg mL-1 Kcrown:RF M-1 enhancement % 
12C4 (1 mg mL-1) 0.074 ± 0.003 2.39 -9 ** 
15C5 (1 mg mL-1) 0.094 ± 0.002 2.87 16 ** 
18C6 (1 mg mL-1) 0.095 ± 0.003 3.35 17 ** 
12C4 (30 mg mL-1) 0.110 ± 0.004 2.39 36 **  
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15C5 (30 mg mL-1) 0.118 ± 0.003 2.87   46 *** 
18C6 (30 mg mL-1) 0.115 ± 0.003 3.35   42 *** 
**P<0.005,   ***P<0.001, one way ANOVA, n = 3. 
 
 
The trend shows that crown ethers have increasing riboflavin binding affinity and solubility 
enhancing properties as the molecule size increases. Complex formation depends on the relative 
size of the host cavity and the guest molecule.15,16,39,40  Riboflavin is too large to reside within the 
cavity of any of the crown ethers investigated in this study,28 however partial complexation is 
possible and more likely with the larger molecular variants and this could reasonably explain the 
increasing solubility of riboflavin as larger crown ethers are used. Further studies of the nature of 
the complexation between crown ethers and riboflavin could potentially be conducted using other 
techniques, e.g. NMR spectroscopy, but this is outside of the scope of the present work.   
Isothermal titration calorimetry analysis of crown ether / Ca2+ 
ITC was used to determine Ca2+ binding efficiency of 5 mM 12C4, 15C5 and 18C6 solutions at 
physiological pH 7.4. Figure 2 shows individual raw data and corresponding isotherms of the 
respective compounds titrated with CaCl2.  Fitting of the isotherm curves is poorer for crown ethers 
in comparison with other chelating agent reported by us in a previous study,15 evident by the lack 
of any distinct transition seen in the isotherms.   
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Figure 2  Isotherms for Ca2+ titration of 5 mmol 12C4, 15C5 and 18C6 crown ether solutions 
titrated using 100 mmol CaCl2. 
Measured values of enthalpy (ΔH), stoichiometry (N), binding affinity (Kb) and entropy (ΔS) 
from this analysis are shown in Table 2   
 
Table 2   ITC analysis at pH 7.4 ± 0.2 of 12C4, 15C5 and 18C6 crown ethers titrated with CaCl2. 
Chelator in  
10 mM MES 
CaCl2 in  
10 mM MES  
Stoichiometry 
      [N] 
Binding affinity  
     [Kb] (M-1) 
     ΔH  
(kJ mol-1) 
ΔS 
(J mol-1 deg-1) 
12C4  (5mM) 100  mM 1.99  ± 0.06      4.47 ± 1.37  -2.50 ± 0.22 -0.89 ± 0.18 
15C5  (5mM) 100  mM 2.43  ± 0.03      4.36 ± 1.02  -1.84 ± 0.06 1.32 ± 0.22 
18C6  (5mM) 100  mM 1.60  ± 0.07      4.20 ± 3.20   -4.11 ± 0.24 -6.35 ± 0.91 
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There is a strong interest of researchers in the studies of complexation between crown ethers and 
various cations.41-43 A number of studies has been published on the analysis of complexation 
thermodynamics in these systems. Many of these studies were conducted using organic solvents, 
which is not relevant to interactions in biological systems. There is also lack of studies of the 
complexation between crown ethers and calcium ions in aqueous media.  Izatt et al44 have  used 
calorimetric titration procedure to study the 1:1 reactions between 15-crown-5 and 18-crown-6 and 
several uni- and bivalent cations at 25 C in aqueous solutions. However, they did not  record any 
measurable heat effects for the complexation of 15C5 with Ca2+ and observed only very weak 
interactions between 18C6 and Ca2+. Solov’ev et al45 later used solution calorimetry and 43Ca NMR 
spectroscopy to study the thermodynamics of the complexation of 18C6 with calcium chloride and 
nitrate in aqueous solutions in a broad range of concentrations. They reported ΔH and ΔS values 
of CaCl2 complexation with 18C6 to be -9.44±2.18 kJ mol-1 and -22.9±7.3 J mol-1 K-1, which is 
greater compared to the values observed in our work. The discrepancy between our results and the 
data reported by Solov’ev et al45 could be due to the difference in the calorimetric equipment and 
protocols used in both studies.  
 
 
Ca2+ extraction from bovine cornea using crown ethers 
Crown ethers are known for their ability to sequester metal ions, the efficiency of this effect 
depends on many factors, for example, cavity size, enthalpy and pH.39,40  Smaller metal ions 
deform the chelate ring to make interactions stronger between the metal ion and oxygen atoms 
within the molecule, whilst larger ions reside close to but outside the cavity.15 Here, the ability of 
12C4, 15C5 and 18C6 crown ether solutions to extract Ca2+ ions from bovine cornea was 
investigated using atomic absorption spectrometry. Using the ‘whole eye method’,28 1 mL of 20 
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mg mL-1 solutions of 12C4, 15C5 and 18C6 crown ethers in PBS at pH 7.4 ± 0.2 were exposed to 
an area of bovine cornea (1.54 ± 0.22 cm2) for 3 hours. Three fresh eyes were used for each crown 
ether solution and after exposure the solutions were recovered, centrifuged for 10 minutes at 10000 
rpm and the supernatant was diluted in 0.25 w/v aqueous LaCl3 solution for AAS analysis.  This 
investigation has shown that PBS has the ability to absorb Ca2+ ions and this is likely to be due to 
dissolving soluble mucins from the ocular surface. Crown ethers are able to sequester Ca2+ from 
the cornea above this ‘background’ level.46 Figure 3 shows differences in calcium content of 
solutions before corneal exposure compared to the same solutions after exposure to the cornea.  
All formulations show a net increase in Ca2+ concentration at the end of this experiment and the 
rank order of calcium sequestering performance from bovine cornea compared to PBS is;  PBS 
(54.67 ± 7.04 ppm) < 12C4** (62.58 ± 1.10 ppm) < 15C5** (69.42 ± 0.65 ppm) < 18C6* (81.39 
± 1.38 ppm). * P < 0.05, ** P < 0.01, *** P < 0.001, one-way ANOVA, n = 3. 
 
 
Figure 3  Ca2+ concentration in solutions of crown ethers (20 mg mL-1) in PBS before and after 3 
hours exposure to bovine cornea. * P < 0.05, ** P < 0.01, *** P < 0.001, one way ANOVA, n = 
3. 
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Effect of crown ethers on permeability of riboflavin through bovine cornea 
In vitro studies using Franz diffusion cells were carried out to investigate any permeability 
enhancement of riboflavin using crown ethers. The receiving chamber was filled with PBS at 
physiological pH (16.5 mL) and 1 mL of each crown ether solution in PBS incorporating 0.08 mg 
mL-1 riboflavin was added to the epithelial side of the cornea. 200 µL aliquots were taken for 
HPLC analysis every 60 minutes for 240 minutes. Experiments were carried out in triplicate and 
analysis was carried out at the time of sampling to prevent sample degradation. Results are reported 
as the mean ± standard deviation. Statistical analysis by ANOVA was applied and P values <0.05 
were considered significant. Figure 4a shows the overlaid riboflavin permeability profiles for 
crown ethers at 1 mg mL-1, Figure 4b shows the graphs for crown ethers at 30 mg mL-1, error bars 
have not been included for clarity. The same profiles are shown individually with error bars in 
supporting information (Figure S1).  The results show that 12C4, 15C5 and 18C6 crown ethers at 
1 mg mL-1 all afford a moderate enhancement in riboflavin permeability across bovine cornea to 
22 ± 6, 19 ± 7 and 14 ± 4 ng mL-1 at 240 minutes respectively compared to riboflavin in PBS which 
is 8 ± 2 ng mL-1, whilst at 30 mg mL-1 they offer a significant enhancement at 62 ± 23, 35±4 and 
33 ± 7 ng mL-1 respectively.  There is no significant difference in riboflavin permeability 
enhancement between the different crown ethers except for the difference between 12C4 and 18C6 
at 30 mg mL-1.      
Apparent permeability and steady state flux were calculated using Equation 3 and the results are 
given in Table 3.   
Table 3   Steady state flux and apparent permeability of riboflavin through bovine cornea in PBS 
with and without crown ether. 
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Solution Steady-state flux,   
(µmol min-1) 
Papp  
(cm s-1 × 10-3) 
 PBS 0.0478 1.945 
12C4 1 mg mL-1 0.1208 6.138 
15C5 1 mg mL-1 0.1074 5.457 
18C6 1 mg mL-1 0.0753 3.826 
12C4 30 mg mL-1 0.341 17.326 
15C5 30 mg mL-1 0.1961 9.964 
18C6 30 mg mL-1 0.1811 9.202 
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Figure 4  Permeability profiles for riboflavin in crown ether / PBS solutions through bovine 
cornea. Crown ethers at 1 mg mL-1 (a), 30 mg mL-1 (b) * P < 0.05, ** P < 0.01, *** P < 0.001, 
one way ANOVA, n = 3. 
 
Comparing riboflavin permeability enhancing performance between crown ethers and 
polyaminocarboxylic acids at the same concentration (1 mg mL-1) and with riboflavin 
concentration at 0.08 mg mL-1 it has been shown that crown ethers have superior permeability 
enhancing properties (Table 4). The smallest crown ether molecular variant offered the best 
performance. 
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Table 4  Bovine cornea permeation of riboflavin using polyaminocarboxylic acids and crown 
ethers. 
Enhancer,  1 mg mL-1 Riboflavin, µmol 
EDTA 0.032 ± 0.007 
EGTA 0.035 ± 0.004 
EDDS 0.025 ± 0.010 
12C4 0.059 ± 0.016 
15C5 0.052 ± 0.018 
18C6 0.036 ± 0.011 
 
Effect of crown ethers on riboflavin penetration into bovine cornea 
When treating corneal disorders such as keratoconus, it is essential that riboflavin is taken up by 
the stroma where UVA collagen cross-linking is facilitated.5 Therefore, crown ether mediated 
riboflavin transport into the cornea was evaluated. 
Corneas from the above diffusion studies were trimmed to exclude limbal and scleral tissue.  
Riboflavin was extracted using absolute ethanol with subsequent analysis using HPLC. It was 
found that all the crown ethers investigated enhanced corneal absorption of riboflavin significantly 
greater than riboflavin in PBS alone.  At 1 mg mL-1 there was an increasing concentration of 
riboflavin extract from the corneas; 0.470 ±  0.003 ng mg -1 for 12C4,*** 0.930 ± 0.145 ng mg -1 
for 15C5*** and 1.450 ± 0.182 ng mg -1 for 18C6.**  At 30 mg mL-1 there was a further increase 
in riboflavin extract, however the trend reversed with the highest concentration for 12C4 at 1.790 
± 0.245 ng mg -1***, reducing to 1.510 ± 0.164 ng mg -1  for 15C5*** and to 1.00 ± 0.1975 ng mg 
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-1 for 18C6.***  Table 5 lists the amounts of riboflavin extracted from bovine corneas after 
exposure to PBS with and without crown ether after 4 hours exposure.  * P < 0.05, ** P < 0.01, 
*** P < 0.001, one way ANOVA, n = 3. 
 
 
Table 5  Riboflavin extracted from treated corneas after 4 hours exposure, ng mg-1. 
Crown ether solution in PBS  
with 0.08 mg mL-1 riboflavin 
Riboflavin,  
ng mg-1 cornea 
PBS 0.060 ± 0.001 
12C4  1 mg mL-1 0.470 ± 0.003*** 
15C5  1 mg mL-1 0.930 ± 0.145*** 
18C6  1 mg mL-1 1.450 ± 0.182** 
12C4 30 mg mL-1 1.790 ± 0.245*** 
15C5 30 mg mL-1 1.510 ± 0.164*** 
18C6 30 mg mL-1 1.000 ± 0.198*** 
                                  * P < 0.05, ** P < 0.01, *** P < 0.001, one way ANOVA, n = 3. 
 
Toxicological investigation 
Epithelial damage is linked to corneal opacity and this phenomenon can be indicative of a 
substances ocular toxicity. Figure 5 shows that the three different crown ethers, 12C4, 15C5 and 
18C6, produce a similar level of epithelial change, and increasing the concentration from 1 mg 
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mL-1 to 30 mg mL-1 does not increase induced opacity. The level of epithelial damage caused by 
crown ethers was similar to that caused by the various concentrations of the BAC compounds and 
was much lower compared with the positive controls, NaOH 0.5 M and 1.0 M, which display a 
high level of corneal opacity due to alkali burning. BAC is often used in ocular formulations in 
concentrations up to 0.02% to act as a penetration enhancer and preservative.47 At higher 
concentration BAC is known to be an irritant and toxic.48 
 
 
Figure 5 Relative intensity of epithelial damage caused by PBS (negative control), BAC 0.02%, 
BAC 0.1%, BAC 0.5%, BAC 1%, BAC 2%, NaOH 0.5M, (positive control) NaOH 1M, positive 
control)  EDTA 1mg mL-1, 12C4 30g mL-1,15C5 1 and 30 mg mL-1 and 18C6 1 and 30 mg mL-1. 
No significant difference between all tested compounds except for the positive controls which 
showed a significantly damaging effect on bovine cornea epithelia.***    *** P < 0.001, one way 
ANOVA, n = 3. 
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Crown ethers display ionophoretic properties in cell membranes and behave similarly to natural 
ionophores, i.e. valinomycin, a cyclicdepsipeptide antibiotic.22,49 Therefore, their toxic effect is 
thought to be due to penetration of the cellular bilayer membrane.50 By applying these 
compounds to the cornea, epithelial disruption allows for permeation of fluorescein dye. Figure 
6 shows that the fluorescent intensity of epithelial surfaces treated with the crown ethers is 
comparable to corneas treated with BAC 1% and 2%.* High permeation of the fluorescein dye 
shows that if the permeability enhancer was to be used in conjunction with a therapeutic 
compound such as riboflavin in eye drop formulations, it would afford assisted transport into the 
cornea and could eliminate the need for invasive epithelial removal. Comparing crown ethers 
with BAC in the concentrations shown suggests they appear to be more toxic than BAC at the 
accepted level (0.02%)* used in many eye drop formulations, but less toxic than BAC 
concentrations >0.1% and EDTA at 1mg mL-1, especially for the 12C4 variant. The positive 
controls 0.5 M NaOH and 1.0 M NaOH were significantly more toxic than all other compounds 
tested.***   * P < 0.05, ** P < 0.01, *** P < 0.001, one way ANOVA, n = 3. 
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Figure 6 Fluorescent intensity of epithelial surface pre-treated with PBS, BAC 0.02% to 2.0%, 
EDTA 1 mg mL-1, NaOH 0.5 M and 1.0 M and crown ether between 1 and 30 mg mL-1, followed 
with fluorescein sodium staining 
 
 
In vivo experiments 
In vivo experiments were conducted in Wistar rats (n=3) to test ocular penetration of riboflavin 
using 0.08 mg mL-1 drug formulations with and without 30 mg mL-1 12C4, the crown ether that 
demonstrated the best penetration enhancement performance in vitro. 2 mL of the drug 
formulations were instilled into both eyes gradually within 40 min (Figure S2). This timing was 
chosen to ensure the practicality of working with live animals and also to keep it relatively close 
to the drug administration procedure used clinically (30 min5).   
Unfortunately, the results of these in vivo experiments did not show any statistically significant  
penetration enhancement effect with 30 mg mL-1 12C4: the amounts of riboflavin extracted from 
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the eyes after the application of the formulations with and without 12C4 were 0.3889±0.0998  and 
0.4855±0.1702 µg g-1, respectively, and the difference between these values is not statistically 
significant (p>0.05).   
 
Additional experiments were performed to evaluate the effect of riboflavin formulations with and 
without 30 mg mL-1 12C4 on the epithelial morphology of rat corneas. Figure 7 shows the 
histological images of rat corneas, following in vivo administration of 1 mL 0.08 mg mL-1  
riboflavin solutions with and without 30 mg mL-1 12C4 during 40 mins.  A comparison of the 
corneal morphology allows conclusions that the use of formulation containing 30 mg mL-1  12C4 
does not lead to any serious epithelial disruption. The epithelial cells remain intact and tightly 
attached to the stroma. Previously, we have reported the disruptive effects of cyclodextrins28 and 
chelating agents15 on the bovine corneas in vitro. However, we did not observe any similar 
disruptive effects in vivo.  
Unfortunately, in vivo experiments did not provide any evidence for penetration enhancement 
effects caused by 12C4.  
 
  
(a)                                                                                      (b) 
30 
 
Figure 7. Histology of rat corneas following in vivo administration of 1 mL 0.08 mg mL-1  
riboflavin solution without (a) and with (b) 30 mg mL-1  12C4 during 40 mins.  Scale bar is 100 
µm.  
 
 
The possible reason for this lack of in vitro – in vivo correlation is the dynamic nature of live 
corneal surfaces that are continuously washed with a tear fluid. During in vitro experiments the 
riboflavin formulations containing crown ethers as penetration enhancers clearly exhibited better 
drug penetration because of the static nature of bovine corneas, giving a possibility for their 
prolonged contact with a biological surface. In vivo the situation is very much different and the 
enhancer is quickly washed off the ocular surface. To test this hypothesis, we have conducted 
additional experiments on fluorescein retention on rat’s cornea in vivo. 1 mg mL-1 sodium 
fluorescein solution was administered on rat’s cornea and UV light was briefly shone into their 
eye to improve its detection, which under these conditions showed green fluorescence. Digital 
images were taken at different time intervals and some exemplary images are shown in Figure 8.  
  
                             0 min                                                                 5 min 
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Figure 8. Retention of 1 mg mL-1 sodium fluorescein on rat’s cornea in vivo. UV light was shone 
to the eye to facilitate the detection of green fluorescence from sodium fluorescein.  
 
It is clearly seen that sodium fluorescein is quickly washed off the corneal surface even within 5 
minutes after ocular administration. This correlates well with our recent report on in vivo retention 
of fluorescein on rabbit corneas in vivo: non-viscous formulations containing fluorescein stayed 
on the corneal surfaces only for a few minutes.51 This lack of in vitro – in vivo correlation clearly 
highlights the need for further in vivo experiments in this area. The majority of in vitro models 
used to study drug retention / penetration into the ocular tissues are quite limited and cannot fully 
mimic the complex physiology of the ocular environment.  
 
Conclusions 
Crown ethers were investigated for their riboflavin solubility enhancing properties which could 
improve the drugs bioavailability. It was found that 12C4 at 1 mg mL-1 offered a slight reduction 
to the solubility of riboflavin whilst 15C5 and 18C6 at 1 mg mL-1 and all the investigated crown 
ethers at higher concentrations offered significant enhancement to riboflavin solubility, thereby 
increasing its availability for use in ocular drug formulations. Permeability enhancement of bovine 
corneas was investigated based on crown ethers ability to sequester metal ions, namely Ca2+, and 
on their ionophoric properties which could potentially improve drug transport across the physical 
barriers of the cornea. Riboflavin transport through bovine cornea was enhanced by all the crown 
ethers investigated and it was found that 12C4 was the most efficient at both concentrations tested 
(1 mg mL-1 and 30 mg mL-1), this could be due the size differences of the crown ether / drug 
complex.  Crown ethers in PBS were found to significantly improve Ca2+ extraction from corneal 
epithelia compared to PBS alone; therefore they have the ability to loosen Ca2+ dependant tight 
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junctions in the epithelial membrane. The permeability enhancing properties of crown ethers were 
shown to be superior compared to polyaminocarboxylic acids investigated in our previous study,15 
however, it is concluded that crown ethers ionophoric properties enhance riboflavin permeability 
more than their Ca2+ sequestering properties.  Further experiments determined that all the crown 
ether solutions investigated were efficient at delivering riboflavin into the corneal stroma and this 
is necessary for effective treatment following established UV ‘A’ induced collagen cross linking 
for the treatment of keratoconus and other conditions of the cornea.  Crown ethers are novel 
compounds which have not previously been investigated for ocular drug delivery prior to this 
study, therefore an assessment of potential toxicological implications of using crown ethers in 
ocular formulations was carried out and their toxicity was found to be of a similar level to BAC 
which is used as a preservative and penetration enhancer for eye drop medication. Crown ethers at 
1 mg mL-1 and 30 mg mL-1 were shown to have lower epithelial toxicity than EDTA at 1mg mL-
1
. This study has shown that crown ethers have an important role in development of ocular 
medications for improvement of drug solubility, enhanced drug penetration into the cornea and 
potential to eliminate the need for epithelial removal for treatment of corneal disorders. 
Unfortunately, in vivo experiments performed in rats did not establish any significant enhancement 
in riboflavin permeation into the eye mediated with 30 mg mL-1 12C4. The reason for this lack of 
permeability enhancement is the dynamic nature of live ocular tissue that is continuously washed 
with a tear fluid. Additional experiments with fluorescein confirmed that retention on the surface 
of the cornea in vivo is poor. Future research may look at the application of crown ethers in 
combination with mucoadhesive polymers to enhance both the drug permeability and pre-corneal 
retention. Another important finding from these experiments is a clear need for conducting in vivo 
experiments to evaluate the efficiency of a formulation to enhance corneal permeability of drugs. 
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This work clearly demonstrated that experiments with ex vivo corneas could provide valuable 
information about drug permeation and permeability enhancement properties of different agents; 
however, this information is limited and cannot always predict the behaviour of a drug delivery 
system in vivo.  
Further studies will be required to evaluate the potential of crown ethers to enhance corneal 
permeability for other drugs. Additionally, the studies where crown ethers are combined with 
mucoadhesive polymers to enhance drug permeation and to improve pre-corneal retention will be 
of interest. Our recent study of timolol maleate formulations52 demonstrated that the combination 
of permeability enhancers with some mucoadhesive polymers could potentially inhibit drug 
permeation through the cornea despite the improvements in pre-corneal retention, which indicates 
that there is still lack of understanding of permeability enhancement effects in multicomponent 
drug formulations.  
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